within Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P01C_AgentsAgainstLeishmaniasisAndTrypanosomiasis.P01CA03_Fexinidazole;

model Fexinidazole
  extends Pharmacolibrary.Drugs.ATC.P.P01CA03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>P01CA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Fexinidazole is an oral nitroimidazole-based medication indicated for the treatment of human African trypanosomiasis (sleeping sickness), caused by Trypanosoma brucei gambiense. It is the first all-oral regimen for this disease and was approved by the European Medicines Agency and WHO for this indication. It is used in both first and second stage disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following oral administration of fexinidazole in adult patients with sleeping sickness. Parameters are based on PopPK modeling in infected individuals (adults) from a phase II/III clinical study.</p><h4>References</h4><ol><li><p>Burrell-Saward, H, et al., &amp; Croft, SL (2017). Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis. <i>International journal of antimicrobial agents</i> 50(2) 203–209. DOI:<a href=\"https://doi.org/10.1016/j.ijantimicag.2017.01.038\">10.1016/j.ijantimicag.2017.01.038</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28552771/\">https://pubmed.ncbi.nlm.nih.gov/28552771</a></p></li><li><p>Torreele, E, et al., &amp; Pécoul, B (2010). Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. <i>PLoS neglected tropical diseases</i> 4(12) e923–None. DOI:<a href=\"https://doi.org/10.1371/journal.pntd.0000923\">10.1371/journal.pntd.0000923</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21200426/\">https://pubmed.ncbi.nlm.nih.gov/21200426</a></p></li><li><p>Kaiser, M, et al., &amp; Brun, R (2011). Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. <i>Antimicrobial agents and chemotherapy</i> 55(12) 5602–5608. DOI:<a href=\"https://doi.org/10.1128/AAC.00246-11\">10.1128/AAC.00246-11</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21911566/\">https://pubmed.ncbi.nlm.nih.gov/21911566</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Fexinidazole;
